BTK and Bruton-type agammaglobulinemia: Our conclusions (illustrated in Supplemental Figure 8) are based on comprehensive analyses of immunological, functional, transcriptional, and biochemical parameters from diverse human cohorts, including healthy donors, patients who have been treated with BTKi and patients with XLA, and corroborating investigations in WT and Btk–/– mice.